Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Why do you think that both Baker and Orbimed had closed their positions in VERA at the last reporting period in Nov? Has anything changed since then?
PHG
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 Guidance
FWIW, stock up after hours.
https://www.biopharmcatalyst.com/company/EOLS/news/180348
Preliminary Unaudited Net Revenue of Approximately $61 Million for the Fourth Quarter 2023, Representing 40% Growth Over the Prior Year Quarter and a 22% Increase Over the Prior Sequential Quarter
Preliminary Unaudited Net Revenue of Approximately $202 Million for the Full-Year 2023, Representing 36% Growth Over the Prior Year
2024 Net Revenue Guidance of $255 Million to $265 Million, Which Represents 26% to 31% Growth From Preliminary 2023 Results
Evolus, Inc. (NASDAQ:EOLS), a global performance beauty company with a focus on building an aesthetic portfolio, today announced its preliminary, unaudited net revenue for the fourth quarter and full-year ended December 31, 2023. The preliminary unaudited results described in this press release are based on the most current information available to management and are subject to change until the audit of the company's 2023 financial results is completed and the company reports its full financial results for the fourth quarter and full-year 2023, which is anticipated to occur in early March 2024.
"We believe the preliminary results of the fourth quarter and full-year 2023 are clear indications of our strong operational execution and significant market share gains resulting from deeper penetration of the neurotoxin market in the U.S. with Jeuveau® and expansion of our neurotoxin brand, Nuceiva®, in Europe," said David Moatazedi, President and Chief Executive Officer of Evolus. "We are thrilled to have achieved record results and exceeded our guidance for the year, positioning us to carry this strong momentum and drive growth into 2024.
RVNC
The price is certainly depressed compared to most of the stock history.
How long or to what future price would you consider this action "bullish"? Obviously he can't sell and collect a profit for a regulatory period, but beyond that?
CYTK up 17% this AM without top line news. Leaky ship? Should report this week. There is a takeout rumor. All very odd.
RVNC
RVNC
I did listen to the call in real time. Read the transcript afterwards to see how it compared to my impressions. The short summary is RVNC needs to do better. I have no idea how things are going to go this Q or next but it will take at least that long to consider a longer term investment, for me.
Anyone looking at buying here might want to keep in mind that tax loss selling will pick up again and there are still 6+ weeks of that to go through. I have no feel at all for what price may go to in that time frame and there is at least some chance that there will be positive earnings expectations by mid-December, but price here can go lower than it should or that you might expect.
There is about a 50/50 chance I will make a tactical buy near the end of the year for the January effect. Will decide at the time, no rush. As a side note, the tactical buy 'around 8+/-' that I mentioned but did not participate in gets a grade of C- only because there was adequate profit available if one remembered to take it. It would have been a difficult trade to time properly had I been in it and don't regret passing on the trade.
GL
RVNC
MRTX 14A
is kind of interesting, and not in a good way for MRTX shareholders. The history of BMY offers dated back to 03/22 at $125 with a high (non-binding) offer in 04/22 of $140 share, which the board of MRTX wanted to see improved. MRTX was trading around the 80's at the time having fallen from about 200 a few moths prior and an all-time high near 250 in late 2020. Finally accepting $58 plus a $12 CVR. Yes, buyouts can happen at any time but your BOD might screw it up.
https://www.sec.gov/Archives/edgar/data/1576263/000114036123049203/edge20012673x1_prem14a.htm#tBOM
A brief summary via X:
https://twitter.com/fakepharmabro/status/1716576875156275250
When the most vocal bulls stop announcing purchases is the more refined version of that sentiment indicator. Getting closer.
There is still more tax loss selling this month and more in December if it becomes relevant. Me, I'd rather wait on sales north of 25M in consecutive Q's even if it means buying at a higher price (and it might not.)
Getting ready for another tranche?
PFE
NVO LLY more to digest on the FLOW trial, FWIW via @Citrini7
RVNC
Whatever the price may be at some point in the future, whatever risk/reward you think you are taking, this stock is in the penalty box until price stabilizes. Preferably with positive sales etceteras.
There are likely several reasons for the selloff here. Blaming one or another doesn't do any good. Some of those pressures will remain at least until earnings, and earnings has become something like a binary with sales being a primary focus. Whatever the price was last week looks too high.
So yeah, I don't like buying stocks in downtrends. Buy the dip in an uptrend, sure. Downtrend, no.
I think there are two discussions.
Is it a big deal for dialysis patients? Looks like it might be. That's good.
Is it a big deal for DVA et al? I don't know. The point of Ralph's post was that whatever reduction there my be in dialysis, the selloff looked like an overreaction.
I don't have a dog in the fight. If you want to posit that GLP-1 will keep Stage 4 CKD patients in that stage longer, then it takes them longer to get to dialysis. Not that there will be less.
FWIW a comment from a Nephrologist
Having hard time believing, as a kidney doctor, that the data from Ozempic will have such an impact on CKD patients to the level dialysis stocks have reacted. While I believe it will delay CKD progression, a la gliflozin family, I doubt it will be curative. $DVA $NVO $LLY ...
— Ralph (@StuckInStock) October 11, 2023
PHG
More drama on the apnea device recall from 2021, FDA still seeking data.
https://www.cnbc.com/2023/10/06/philips-shares-fall-after-fda-says-sleep-device-recall-inadequate.html
Following your link and just below the quoted section in your post:
RVNC
PFE
More info on Gepirone, a long history.
https://pbs.twimg.com/media/F7I9FY9WMAEMtlP?format=jpg&name=medium